Efficacy Evaluation of Zuogui Pills Combined with Butylphthalide in the Adjuvant Treatment of Mild Cognitive Impairment in Parkinson′s Disease
Objective To investigate the clinical efficacy of Zuogui Pills combined with butylphthalide in the adjuvant treatment of mild cognitive impairment in Parkinson's disease.Methods Eighty patients with mild cognitive impairment in Parkinson's disease admitted to the hospital from January to March 2023 were selected and divided into the observation group and the control group by the random number table method,with 40 cases in each group.The patients in the two groups were given conventional western medicines for Parkinson's disease and Butylphthalide Soft Capsules orally,on this basis,the patients in the observation group were given Zuogui Pills.Both groups were treated continuously for eight weeks.Results The total effective rate in the observation group was 90.00%,which was significantly higher than 70.00%in the control group(P<0.05).After treatment,the scores of traditional Chinese medicine(TCM)syndromes including waist,knee soreness,rib pain,dizziness and headache in the observation group were significantly lower than those in the control group(P<0.05).After treatment,the expression level of silent information regulator 1(SIRT1)protein in the observation group was significantly higher than that in the control group,and the expression level of nuclear factors κB(NF-κB)protein was significantly lower than that in the control group(P<0.05).After treatment,the Montreal Cognitive Assessment(MoCA),Mini-Mental State Examination(MMSE)and Activity of Daily Living(ADL)scores in the observation group were significantly higher than those in the control group(P<0.05).After treatment,the Unified Parkinson's Disease Rating Scale(UPDRS)score in the observation group was significantly lower than that in the control group(P<0.05).The incidence of adverse reactions in the observation group was similar to that in the control group(5.00%vs.2.50%,P>0.05).Conclusion On the basis of conventional treatment,Zuogui Pills combined with butylphthalide in the adjuvant treatment of mild cognitive impairment in Parkinson's disease can decrease patients'TCM syndrome score,improve the expression levels of SIRT1,NF-κB proteins,enhance the cognitive function and activity ability of daily living.
Zuogui PillsbutylphthalideParkinson's diseasemild cognitive impairmentadjuvant treatmenttraditional Chinese medicine syndromeactivity ability of daily livingclinical efficacy
万方数据
维普
